Epstein-Barr virus latent membrane protein 2-derived peptide–HLA class I complex (EBV LMP2–HLA-I complex) (EBV LMP2–HLA-I complex)

The Epstein-Barr virus latent membrane protein 2-derived peptide–HLA class I complex (EBV LMP2–HLA-I complex) is a molecular assembly presented on the surface of cells infected with EBV or EBV-associated malignant cells. It consists of a short peptide fragment (typically 8-11 amino acids) derived from the viral LMP2 protein, non-covalently bound within the peptide-binding groove of a Human Leukocyte Antigen (HLA) class I molecule. This complex serves as a primary target for CD8+ cytotoxic T lymphocytes (CTLs), which recognize the specific peptide-HLA combination through their T-cell receptors (TCRs). In diseases such as nasopharyngeal carcinoma (NPC), Hodgkin lymphoma, and post-transplant lymphoproliferative disease (PTLD), the expression of this complex allows the immune system to distinguish malignant cells from healthy ones. Therapeutic strategies targeting this complex include the adoptive transfer of EBV-specific CTLs, engineered TCR-T cell therapies, and peptide-based vaccines designed to enhance the host's anti-viral and anti-tumor immunity. The efficacy of these treatments is highly dependent on the patient's HLA genotype, as different HLA alleles (e.g., HLA-A*02:01, HLA-A*11:01) present distinct LMP2 epitopes.

Other names

EBV LMP2 pMHC complexLMP2-HLA complexEBV LMP2-MHC class I complexEBV LMP2-derived peptide–MHC class I complexEBV LMP2-derived peptide–HLA class I complex

T-cell receptor (TCR) mediated recognition of the peptide-HLA complex on the surface of infected or malignant cells, leading to T-cell activation, cytokine release (e.g., IFN-gamma), and direct cell-to-cell killing via perforin and granzymes.